CD8A and cancer: Since 4-1BB was used as costimulation domain of CD176-CAR constructs, and the majority of generated CD176-CAR-Ts showed a CD8+ TCM phenotype, both of which are known to mediate long-term persistence in vivo (37, 38), we expect a CD176-targeting immunotherapy to reach a majority of cancer cells of an individual cancer over time.